Autoimmune Diabetes Phenotypes and Management

Autoimmune diabetes encompasses a spectrum of disorders in which the immune system targets pancreatic beta cells, leading to variable degrees of insulin deficiency and metabolic dysregulation. At one end of the spectrum is classical type 1 diabetes, characterised by rapid beta cell destruction and insulin dependence. At the other lies latent autoimmune diabetes in adults (LADA), which presents in later life with slower progression, overlapping features of type 1 and type 2 diabetes, and heterogeneity in autoantibody profiles, genetic predisposition, and metabolic characteristics. Subtypes such as slowly progressive insulin-dependent diabetes mellitus (SPIDDM) further illustrate the gradation of autoimmunity and residual beta cell function. Diagnostic pathways integrate measurement of islet autoantibodies, C-peptide assays to gauge endogenous insulin secretion, and genetic risk assessment. Management strategies are tailored according to phenotype and may include early insulin initiation to preserve beta cell function, immunomodulatory approaches under clinical investigation, and lifestyle interventions aimed at mitigating insulin resistance. Advances in biomarkers, risk stratification and phenotypic characterisation are driving a precision medicine paradigm, enabling clinicians to identify at-risk individuals, personalise therapeutic regimens and improve long-term glycaemic control. This approach addresses global challenges, optimising resource allocation and improving outcomes across diverse populations.

Research from Nature Portfolio

Recent studies have refined clinical criteria for identifying adult-onset autoimmune diabetes using simple measures such as age at diagnosis and estimated glucose disposal rate, enabling primary-care screening of patients who may benefit from autoantibody testing and early insulin therapy. Detailed characterisation of latent autoimmune diabetes in adults in a large cross-sectional cohort revealed distinct metabolic and demographic profiles compared to type 2 diabetes, underscoring the importance of autoantibody stratification in guiding management. Complementary epidemiological analyses have demonstrated that individuals with existing autoimmune diseases face an elevated risk of developing type 2 diabetes, suggesting shared inflammatory mechanisms and an expanded continuum of autoimmune involvement beyond classical type 1 diabetes.

Autoimmune Diabetes Phenotypes and Management publication trend

The graph below shows the total number of articles in autoimmune diabetes phenotypes and management across all publications each year (not limited to Nature Index journals).

Technical terms

Latent autoimmune diabetes in adults (LADA): An adult-onset form of autoimmune diabetes with mixed features of type 1 and type 2 diabetes, marked by islet autoantibody presence and gradual beta cell decline.

Autoantibody: An antibody produced by the immune system that recognises and binds to the body’s own proteins, such as those in pancreatic islet cells.

Estimated glucose disposal rate (eGDR): A calculated index of insulin sensitivity based on clinical parameters, used to assess risk of insulin resistance and guide management.

Glutamic acid decarboxylase autoantibody (GAD65): An autoantibody targeting a key enzyme in beta cells, commonly employed as a biomarker of autoimmune diabetes.

C-peptide: A peptide released during endogenous insulin synthesis, used as an indicator of residual beta cell function.

References

1. Antioxidant Nutrients and Risk of Latent Autoimmune Diabetes in Adults and Type 2 Diabetes: A Swedish Case-Control Study and Mendelian Randomization Analysis. Nutrients (2023).
2. Overweight, obesity and the risk of LADA: results from a Swedish case–control study and the Norwegian HUNT Study. Diabetologia (2018).
3. Subsequent Type 2 Diabetes in Patients with Autoimmune Disease. Scientific Reports (2015).
4. Autoimmunity plays a role in the onset of diabetes after 40 years of age. Diabetologia (2019).
5. Identification and phenotypic characterization of patients with LADA in a population of southeast Mexico. Scientific Reports (2023).